Inventor · disambiguated record
Michelle L. Hastings
Also filed as: HASTINGS MICHELLE L
13 granted patents·8 pending applications·28 citations·filing 2011–2024
88Inventor score
Top patents by PatentIndex Score
21 records- 0190US9840709B2Antisense compounds targeting genes associated with cystic fibrosisUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2016·Granted Dec 12, 2017·5 cites·26 claims
- 0288US10525076B2Antisense compounds targeting genes associated with cystic fibrosisUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2017·Granted Jan 7, 2020·3 cites·30 claims
- 0388US9840710B2Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons diseaseUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2016·Granted Dec 12, 2017·6 cites·14 claims
- 0487US11116785B2Antisense compounds targeting genes associated with cystic fibrosisUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2019·Granted Sep 14, 2021·2 cites·33 claims
- 0587US10544417B2Antisense compounds targeting genes associated with cystic fibrosisUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2017·Granted Jan 28, 2020·3 cites·31 claims
- 0685US11732260B2Compounds and methods for the modulation of amyloid-β precursor proteinIONIS PHARMACEUTICALS INC·Filed 2019·Granted Aug 22, 2023·2 cites·39 claims
- 0784US9353371B2Antisense compounds targeting genes associated with usher syndromeHASTINGS MICHELLE L·Filed 2012·Granted May 31, 2016·5 cites·15 claims
- 0882US2025354147A1Antisense Compounds Targeted to CLN3 and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0980US8648053B2Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndromeHASTINGS MICHELLE L·Filed 2012·Granted Feb 11, 2014·2 cites·21 claims
- 1076US12042508B2Antisense compounds targeting genes associated with cystic fibrosisUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2021·Granted Jul 23, 2024·0 cites·27 claims
- 1168US2025049838A1Antisense Compounds Targeting Genes Associated with Cystic FibrosisUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2024·Application pending·0 cites
- 1267US2020216846A1Antisense Compounds and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1366US10787669B2Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons diseaseUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2019·Granted Sep 29, 2020·0 cites·27 claims
- 1464US2017268000A1Antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1561US9556434B2Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for usher syndromeUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2015·Granted Jan 31, 2017·0 cites·15 claims
- 1660US2014243388A1Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndromeUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2014·Application pending·0 cites
- 1759US10370667B2Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons diseaseUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2017·Granted Aug 6, 2019·0 cites·16 claims
- 1859US2021401869A1Antisense Compounds Targeting Genes Associated with Cystic FibrosisUNIV ROSALIND FRANKLIN MEDICINE & SCIENCE·Filed 2021·Application pending·0 cites
- 1951US2022280545A1Compounds and methods for modulating cln3 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2050US10472634B2Antisense compounds targeting apolipoprotein E receptor 2IONIS PHARMACEUTICALS INC·Filed 2015·Granted Nov 12, 2019·0 cites·19 claims
- 2143US2012165389A1Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndromeHASTINGS MICHELLE L·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →